Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation.
Jihoon KimTae-Seok SeoHyunsoo KimHyejeong ParkTaek Kyu ParkJoo-Myung LeeJeong Hoon YangYoung Bin SongJin Ho ChoiSeung-Hyuk ChoiHyeon Cheol GwonEliseo GuallarJuhee ChoJoo-Yong HahnPublished in: Journal of Korean medical science (2024)
As an antithrombotic therapy for AF beyond one year after coronary revascularization, NOAC monotherapy was associated with a similar risk of MACCE and a lower risk of major bleeding compared to NOAC plus antiplatelet combination therapy.
Keyphrases
- combination therapy
- atrial fibrillation
- oral anticoagulants
- percutaneous coronary intervention
- coronary artery disease
- coronary artery
- coronary artery bypass grafting
- heart failure
- stem cells
- randomized controlled trial
- clinical trial
- left ventricular
- open label
- bone marrow
- study protocol
- aortic valve
- ejection fraction